“…However, several studies included further specifications for patient inclusion namely age [ 12 ], cerebral amyloid related angiopathy [ 13 ], deep location [ 14 – 17 ], lobar location [ 18 ], supratentorial bleeds [ 16 , 19 – 33 ], presence of intraventricular hemorrhage [ 16 , 34 , 35 ], African ethnicity [ 36 ], non-comatose patients [ 22 , 37 ], comatose patients [ 38 ], medically treated patients [ 22 – 25 , 27 , 33 , 38 – 40 ], surgically treated patients [ 21 ], oral anticoagulant related bleeds [ 41 ], hypertensive patients [ 19 , 36 ], and dialysis patients [ 40 ]. The majority of studies ( n = 40) recruited patients from hospitals or emergency rooms [ 10 – 14 , 16 – 22 , 26 , 29 – 31 , 36 , 40 – 61 ] but nine studies recruited patients from intensive care units [ 24 , 28 , 32 , 33 , 35 , 38 , 62 – 64 ], three studies recruited patients from stroke units [ 34 , 37 , 65 ], six studies recruited patients from neurology/neurosurgery departments [ 15 , 25 , 27 , 39 , 66 , 67 ], and one study recruited patients from both an intensive care unit and a stroke unit [ 23 ]. Most prognostic tools were derived from cohort studies, with the exceptions being registries [ 29 , …”